Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus induction and consolidation chemotherapy in newly diagnosed AML or MDS-EB2
2020-004453-71Phase 3Active
- Sponsor
- University Hospital Ulm
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) and Myelodysplastic neoplasm with increased blasts 2 (MDS-IB2) comparing Venetoclax plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoint: Event-free survival. Started Jul 2021; status: active.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)Myelodysplastic neoplasm with increased blasts 2 (MDS-IB2)
Beyond the preview
Go deeper on 2020-004453-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004453-71.